(Q40387534)

20 September 2017

title

Mechanisms of statin-mediated inhibition of small G-protein function (English)

1 reference

20 September 2017

Andrew Cordle

1

1 reference

20 September 2017

Jessica Koenigsknecht-Talboo

2

1 reference

20 September 2017

Brandy Wilkinson

3

1 reference

20 September 2017

Allison Limpert

4

1 reference

20 September 2017

Gary Landreth

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

4 August 2005

1 reference

Journal of Biological Chemistry

20 September 2017

published in

1 reference

20 September 2017

volume

280

1 reference

20 September 2017

issue

40

1 reference

20 September 2017

page(s)

34202-34209

1 reference

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Protein prenylation: molecular mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

NOX enzymes and the biology of reactive oxygen

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Statins as potential therapeutic agents in neuroinflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Alzheimer beta-amyloid peptide 25-35: electrostatic interactions with phospholipid membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Cytosolic phospholipase A2 (cPLA2) regulation of human monocyte NADPH oxidase activity. cPLA2 affects translocation but not phosphorylation of p67(phox) and p47(phox).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Mapping the binding site for the GTP-binding protein Rac-1 on its inhibitor RhoGDI-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Potential Role of Statins in Inflammation and Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Impact of HMG CoA reductase inhibition on small GTPases in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Do statins slow down Alzheimer's disease? A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Statins inhibit HIV-1 infection by down-regulating Rho activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Rho GTPases and signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Statin therapy for Alzheimer's disease: will it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Cholesterol in Alzheimer's disease and tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M505268200

21 January 2018

Identifiers

DOI

10.1074/JBC.M505268200

1 reference

20 September 2017

1 reference